ストックスクリーナーアプリを入手
0.4313
5.14%
0.0211
プレマーケット:
.43
-0.0013
-0.30%
前日終値:
$0.4102
開ける：
$0.43
24時間の取引高:
507.61K
Relative Volume:
0.49
時価総額：
$11.29M
収益：
-
当期純損益:
$-26.56M
株価収益率:
-0.6635
EPS:
-0.65
ネットキャッシュフロー:
$-22.29M
1週間 パフォーマンス:
+7.82%
1か月 パフォーマンス:
-15.20%
6か月 パフォーマンス:
-41.30%
1年 パフォーマンス:
-80.84%
1日の値動き範囲:
$0.41
$0.435
1週間の範囲:
$0.3758
$0.435
52週間の値動き範囲:
$0.34
$2.637
BiomX Inc Stock (PHGE) Company Profile
名前
BiomX Inc
セクター
電話
972 7 23942377
住所
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
PHGE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PHGE
BiomX Inc
|
0.4313 | 10.47M | 0 | -26.56M | -22.29M | -0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
BiomX Inc Stock (PHGE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-04-15 | 開始されました | Ladenburg Thalmann | Buy |
BiomX Inc (PHGE) 最新ニュース
What analysts say about BiomX Inc. stockSkyrocketing returns - jammulinksnews.com
Is BiomX Inc. a good long term investmentFree Investment Risk Control - jammulinksnews.com
What drives BiomX Inc. stock priceSpectacular growth rates - jammulinksnews.com
BiomX Inc. Stock Analysis and ForecastFree Popular Stock Recommendations - jammulinksnews.com
Should I buy BiomX Inc. stock before earningsHigh Return Stock Alerts - Newser
How BiomX Inc. stock performs during market volatilityFree Signals Group - Newser
What makes BiomX Inc. stock price move sharplyFree Access to Stock Community - Newser
Why BiomX Inc. stock attracts strong analyst attentionCapital Efficient Investment Tips - Newser
BiomX stock holds Buy rating at H.C. Wainwright as Phase 2b trial begins - Investing.com Canada
BiomX doses first subject in Phase IIb trial of cystic fibrosis treatment - Yahoo Finance
BiomX stock maintains Buy rating at H.C. Wainwright with $15 price target - Investing.com India
BiomX stock maintains Buy rating at H.C. Wainwright with $15 price target By Investing.com - Investing.com South Africa
BiomX Stock Drops 7.23% Despite Phase 2b Trial Milestone - AInvest
BiomX announces successful initiation of Phase 2b trial - TipRanks
Market Alert: BiomX Trading Surges Following Phase 2b Trial Initiation in Cystic Fibrosis Program - openPR.com
Biomx Inc. shares fall 5.21% after-hours following the initiation of Phase 2b trial for BX004. - AInvest
BiomX Initiates Phase 2b Trial for BX004, a Phage Therapy Targeting Antibiotic-Resistant Lung Infections in Cystic Fibrosis Patients. - AInvest
Biomx Inc. Announces Successful Initiation of Phase 2B Trial with First Patient Dosed in Bx004 Program in Patients with Cystic Fibrosis - MarketScreener
BiomX stock soars after initiating Phase 2b trial for cystic fibrosis therapy - Investing.com Australia
BiomX Shares Surge 60% Following Start of Phase 2b Trial for Cystic Fibrosis Treatment - MSN
BiomX Doses First Patient in Phase 2b of Cystic Fibrosis Trial - MarketScreener
BiomX begins phase 2b trial for phage therapy targeting CF infections - Investing.com Australia
BiomX begins phase 2b trial for phage therapy targeting CF infections By Investing.com - Investing.com South Africa
BiomX Inc. Initiates First Patient Dosing in Phase 2b Trial for BX004 Targeting Antibiotic-Resistant Lung Infections in Cystic Fibrosis Patients - Nasdaq
BiomX Announces Successful Initiation of Phase 2b Trial - GlobeNewswire
Breakthrough Cystic Fibrosis Treatment Enters Phase 2b Trial After 14% Complete Infection Clearance - Stock Titan
BiomX (NYSEMKT:PHGE) Trading Down 43.3% – Here’s What Happened - Defense World
BiomX Publishes Promising Phase 1b/2a Trial Results - TipRanks
BiomX’s “Bacteria-Eating Virus” Therapy Shows 500-Fold Reduction in Deadly CF Infections: Company Announces Major Scientific Validation in Key Publication - newsblaze.com
BiomX announces publication on BX004 Phase 1b/2a Part 1 data - TipRanks
BiomX Announces Publication in Nature Communications of - GlobeNewswire
Nature Communications Validates BiomX's Breakthrough: 500-fold Bacteria Reduction in Cystic Fibrosis Trial - Stock Titan
Red White & Bloom Brands Provides Update on Status of Annual Filings - The Globe and Mail
This $13M Biotech Has $40M in Pentagon Funding – Here’s Why BiomX Could Be Biotech’s Best-Kept Secret - FinancialContent
This $13M Biotech Has $40M In Pentagon Funding Here's Why Biomx Could Be Biotech's Best-Kept Secret - MenaFN
PHGE SEC FilingsBiomx Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BiomX Inc. Achieves Breakthrough in Treating Antibiotic-Resistant Infections - citybuzz -
BiomX Stock Could Soar 3000% As This $10M Biotech Cracks The 'Superbug' Code, Wall Street Says - FinancialContent
BiomX Highlights Progress in Phage Therapy Advancements - TipRanks
BiomX (NYSEAMERICAN:PHGE) Shares Down 4.3% – Here’s What Happened - Defense World
Biomx stock plunges to 52-week low, hitting $0.47 By Investing.com - Investing.com South Africa
BiomX Inc (PHGE) 財務データ
収益
当期純利益
現金流量
EPS
0.51%
大文字化:
|
ボリューム (24 時間):